Humanized anti-CD117 Monoclonal Antibody (JSP191)
JAS-BMT-CP-001
Phase 2 mab terminated
Quick answer
Humanized anti-CD117 Monoclonal Antibody (JSP191) for SCID is a Phase 2 program (mab) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jasper Therapeutics
- Indication
- SCID
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated